French dermatology-focused drugmaker Galderma Laboratories says interim findings from a study of sequential treatment of plaque psoriasis using Clobex (clobetasol propionate) spray 0.05% followed by treatment with Vectical (calcitriol) ointment 3mcg/g showed positive results.
While both products are indicated for the treatment of plaque psoriasis, this study was conducted to confirm the safety and efficacy of these products when used in a sequential regimen. In this study, Clobex spray was used in the initial phase of the study to treat moderate-to-severe plaque psoriasis. For subjects sufficiently clear at the end of four weeks, Vectical ointment was applied twice-daily for eight weeks. Success was evaluated at week-12 based on Overall Disease Severity scores.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze